# Inetetamab Combined With Paclitaxel With/Without Pertuzumab for Previously Treated HER2-positive Advanced Breast Cancer

> **NCT06578299** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Fudan University** · enrollment: 100 (estimated)

## Conditions studied

- Breast Cancer Stage IV

## Interventions

- **DRUG:** Inetetamab and Paclitaxel ± Pertuzumab

## Key facts

- **NCT ID:** NCT06578299
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-08-30
- **Primary completion:** 2026-03-30
- **Final completion:** 2027-08-30
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2024-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06578299

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06578299, "Inetetamab Combined With Paclitaxel With/Without Pertuzumab for Previously Treated HER2-positive Advanced Breast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06578299. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*